Treating liver fibrosis and metabolic dysfunction-associated steatohepatitis: Research identifies novel mechanism

Published Date: 19 Feb 2025

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and hepatocellular carcinoma. While fibroblast growth factor 21 (FGF21) analogs have shown promise in clinical trials, ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How access to specialized cancer centers affects glioblastoma outcomes

2.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

3.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

4.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

5.

Beyond What Is Visible in Myelofibrosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot